180 related articles for article (PubMed ID: 30390642)
1. Performance of prostate cancer recurrence nomograms by obesity status: a retrospective analysis of a radical prostatectomy cohort.
Zeigler-Johnson C; Hudson A; Glanz K; Spangler E; Morales KH
BMC Cancer; 2018 Nov; 18(1):1061. PubMed ID: 30390642
[TBL] [Abstract][Full Text] [Related]
2. Validation of two preoperative Kattan nomograms predicting recurrence after radical prostatectomy for localized prostate cancer in Turkey: a multicenter study of the Uro-oncology Society.
Eskicorapci SY; Türkeri L; Karabulut E; Cal C; Akpinar H; Baltaci S; Baykal K; ; Kattan MW; Ozen H
Urology; 2009 Dec; 74(6):1289-95. PubMed ID: 19589584
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
Tamblyn DJ; Chopra S; Yu C; Kattan MW; Pinnock C; Kopsaftis T
BJU Int; 2011 Nov; 108 Suppl 2():51-6. PubMed ID: 22085129
[TBL] [Abstract][Full Text] [Related]
4. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
[TBL] [Abstract][Full Text] [Related]
5. Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression.
Schiffmann J; Salomon G; Tilki D; Budäus L; Karakiewicz PI; Leyh-Bannurah SR; Pompe RS; Haese A; Heinzer H; Huland H; Graefen M; Tennstedt P
Urol Oncol; 2017 May; 35(5):243-249. PubMed ID: 28161322
[TBL] [Abstract][Full Text] [Related]
6. External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer.
Roumiguié M; Beauval JB; Filleron T; Benoit T; Rischmann P; de la Taille A; Salomon L; Soulié M; Malavaud B; Ploussard G
BJU Int; 2014 Dec; 114(6b):E113-E119. PubMed ID: 24684584
[TBL] [Abstract][Full Text] [Related]
7. Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram.
Thanigasalam R; Rasiah KK; Stricker PD; Haynes AM; Sutherland SI; Sutherland RL; Henshall SM; Horvath LG
BJU Int; 2010 Mar; 105(5):642-7. PubMed ID: 19751263
[TBL] [Abstract][Full Text] [Related]
8. Genetic predisposition to early recurrence in clinically localized prostate cancer.
Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
[TBL] [Abstract][Full Text] [Related]
9. Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group.
Teeter AE; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
Urology; 2013 Jul; 82(1):53-8. PubMed ID: 23806388
[TBL] [Abstract][Full Text] [Related]
10. Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy.
Rouprêt M; Hupertan V; Comperat E; Drouin SJ; Phé V; Xylinas E; Demanse D; Sibony M; Richard F; Cussenot O
BJU Int; 2009 Sep; 104(6):813-7; discussion 817-8. PubMed ID: 19254280
[TBL] [Abstract][Full Text] [Related]
11. Construction of a Preoperative Radiologic-Risk Signature for Predicting the Pathologic Status of Prostate Cancer at Radical Prostatectomy.
Qi L; Wu CJ; Zhang J; Bao ML; Yan X; Zhang YD
AJR Am J Roentgenol; 2018 Oct; 211(4):805-811. PubMed ID: 29995494
[TBL] [Abstract][Full Text] [Related]
12. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure).
Greene KL; Meng MV; Elkin EP; Cooperberg MR; Pasta DJ; Kattan MW; Wallace K; Carroll PR
J Urol; 2004 Jun; 171(6 Pt 1):2255-9. PubMed ID: 15126797
[TBL] [Abstract][Full Text] [Related]
13. Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men.
Salgado-Montilla J; Soto Salgado M; Surillo Trautmann B; Sánchez-Ortiz R; Irizarry-Ramírez M
Lipids Health Dis; 2015 Sep; 14():111. PubMed ID: 26377420
[TBL] [Abstract][Full Text] [Related]
14. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.
Walz J; Chun FK; Klein EA; Reuther A; Saad F; Graefen M; Huland H; Karakiewicz PI
J Urol; 2009 Feb; 181(2):601-7; discussion 607-8. PubMed ID: 19084864
[TBL] [Abstract][Full Text] [Related]
15. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
Moul JW; Connelly RR; Lubeck DP; Bauer JJ; Sun L; Flanders SC; Grossfeld GD; Carroll PR
J Urol; 2001 Oct; 166(4):1322-7. PubMed ID: 11547066
[TBL] [Abstract][Full Text] [Related]
16. [Can nomograms derived in the U.S. applied to German patients? A study about the validation of preoperative nomograms predicting the risk of recurrence after radical prostatectomy].
Graefen M; Augustin H; Karakiewicz PI; Hammerer PG; Haese A; Palisaar J; Fernandez S; Noldus J; Erbersdobler A; Cagiannos I; Scardino PT; Kattan MW; Huland H
Urologe A; 2003 May; 42(5):685-92. PubMed ID: 12750804
[TBL] [Abstract][Full Text] [Related]
17. Obesity and long-term survival after radical prostatectomy.
Chalfin HJ; Lee SB; Jeong BC; Freedland SJ; Alai H; Feng Z; Trock BJ; Partin AW; Humphreys E; Walsh PC; Han M
J Urol; 2014 Oct; 192(4):1100-4. PubMed ID: 24769031
[TBL] [Abstract][Full Text] [Related]
18. Predictive models and risk of biopsy progression in active surveillance patients.
Iremashvili V; Manoharan M; Kava BR; Parekh DJ; Punnen S
Urol Oncol; 2017 Feb; 35(2):37.e1-37.e8. PubMed ID: 27692836
[TBL] [Abstract][Full Text] [Related]
19. How far is the preoperative Kattan nomogram applicable for the prediction of recurrence after prostatectomy in patients presenting with PSA levels of more than 20 ng/ml? A validation study.
May M; Gunia S; Helke C; Führer S; Hoschke B; Fahlenkamp D; Vogler H; Siegsmund M
Urol Int; 2006; 77(3):222-6. PubMed ID: 17033209
[TBL] [Abstract][Full Text] [Related]
20. The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance.
Ploussard G; de la Taille A; Bayoud Y; Durand X; Terry S; Xylinas E; Allory Y; Vacherot F; Abbou CC; Salomon L
Eur Urol; 2012 Feb; 61(2):356-62. PubMed ID: 21803484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
